Population pharmacokinetics of gemcitabine and dFdU in pancreatic cancer patients using an optimal design, sparse sampling approach.

Date publication

mars 2017

Journal

Therapeutic drug monitoring

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FEIN Francine

Tous les auteurs :
Serdjebi C, Gattacceca F, Seitz JF, Fein F, Gagnière J, François E, Abakar-Mahamat A, Deplanque G, Rachid M, Lacarelle B, Ciccolini J, Dahan L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28346313

Résumé

Gemcitabine remains a pillar in pancreatic cancer treatment. However, toxicities are frequently observed. Dose adjustment based on therapeutic drug monitoring might help decrease the occurrence of toxicities. In this context, this work aims at describing the pharmacokinetics (PK) of gemcitabine and its metabolite dFdU in pancreatic cancer patients and at identifying the main sources of their PK variability using a population pharmacokinetics approach, despite a sparse sampled-population and heterogeneous administration and sampling protocols.

Mots clés

Antimetabolites, Antineoplastic, pharmacokinetics, Cytidine Deaminase, metabolism, Deoxycytidine, analogs & derivatives, Drug Monitoring, methods, Humans, Pancreatic Neoplasms, drug therapy

Référence

Ther Drug Monit. 2017 Mar;: